U.S. markets close in 1 hour 12 minutes
  • S&P 500

    4,418.09
    +6.30 (+0.14%)
     
  • Dow 30

    35,126.88
    +65.33 (+0.19%)
     
  • Nasdaq

    14,835.91
    -1.08 (-0.01%)
     
  • Russell 2000

    2,213.28
    +3.63 (+0.16%)
     
  • Crude Oil

    72.16
    +0.09 (+0.12%)
     
  • Gold

    1,796.70
    -5.10 (-0.28%)
     
  • Silver

    25.24
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1808
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    1.2780
    -0.0080 (-0.62%)
     
  • GBP/USD

    1.3818
    +0.0064 (+0.46%)
     
  • USD/JPY

    110.3700
    -0.1400 (-0.13%)
     
  • BTC-USD

    39,877.53
    +5,462.57 (+15.87%)
     
  • CMC Crypto 200

    946.72
    +31.24 (+3.41%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Galapagos loses partner on inflammatory bowel drug

BRUSSELS, Dec 16 (Reuters) - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a programme to develop a new drug to treat bowel disease.

Galapagos said it had received all rights to the GPR84 inhibitor programme which included the drug GLPG1205 and said it would continue with a phase 2 study of its own on patients with inflammatory bowel disease ulcerative colitis.

The group gave no financial details about the transaction.

It still has a string of drugs developments in its pipeline with pharmaceutical groups such as AbbVie, GSK and Servier.

(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)